# A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

> **NCT00320541** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 187 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** paclitaxel
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00320541
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-04
- **Final completion:** 2012-08
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2013-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320541, "A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00320541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*